{"unnormalised": "AIIMS Delhi recently announced a breakthrough in cancer treatment for advanced-stage patients. Dr. Rajesh Kumar, head of Oncology, revealed the results of a clinical trial involving a new immunotherapy drug. The trial, conducted over 2 years, showed a significant reduction in tumor size in 60% of participants with Stage IV lung cancer. Patients received the drug alongside standard chemotherapy, with noticeable improvements observed within 3 months.", "normalised": "A-I-I-M-S Delhi recently announced a breakthrough in cancer treatment for advanced-stage patients. Doctor Rajesh Kumar, head of Oncology, revealed the results of a clinical trial involving a new immunotherapy drug. The trial, conducted over two years, showed a significant reduction in tumor size in sixty percent of participants with Stage I-V lung cancer. Patients received the drug alongside standard chemotherapy, with noticeable improvements observed within three months."}
{"unnormalised": "The treatment, tentatively named \"OncoHope,\" targets specific proteins on cancer cells, boosting the body's immune response. A single dose costs approx. Rs. 2.5 lakh, posing accessibility challenges. However, AIIMS is working with govt. to make it affordable for economically weaker sections. One patient, Mrs. Sunita Devi, 55, shared her experience, stating, \"After 6 cycles of chemo, I felt hopeless. But OncoHope gave me a new lease of life.\"", "normalised": "The treatment, tentatively named \"OncoHope,\" targets specific proteins on cancer cells, boosting the body's immune response. A single dose costs approximately rupee two point five lakh, posing accessibility challenges. However, A-I-I-M-S is working with government to make it affordable for economically weaker sections. One patient, Missus Sunita Devi, fifty five, shared her experience, stating, \"After six cycles of chemo, I felt hopeless. But OncoHope gave me a new lease of life.\""}
{"unnormalised": "While OncoHope shows promise, experts caution that it is not a cure-all. Further research is needed to understand its long-term effects and applicability to other cancer types. The findings were published in the \"Indian Journal of Medical Research\" and have generated considerable excitement in the medical community. A national rollout is planned for Q3 2025, pending regulatory approvals from CDSCO.", "normalised": "While OncoHope shows promise, experts caution that it is not a cure-all. Further research is needed to understand its long-term effects and applicability to other cancer types. The findings were published in the \"Indian Journal of Medical Research\" and have generated considerable excitement in the medical community. A national rollout is planned for Q-three two thousand and twenty five, pending regulatory approvals from C-D-S-C-O."}
